UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1021-13
Program Prior Authorization/Notification
Medication Cometriq® (cabozantinib)
P&T Approval Date 02/2013, 07/2013, 8/2014, 8/2015, 6/2016, 6/2017, 6/2018, 6/2019,
6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Cometriq® (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with
progressive, metastatic medullary thyroid cancer (MTC).
In addition, the National Cancer Comprehensive Network (NCCN) recommends Cometriq for the
treatment of medullary, follicular, oncocytic and papillary thyroid carcinomas. NCCN also
recommends Cometriq for the treatment of non-small cell lung cancer (NSCLC) with RET gene
rearrangement.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Cometriq will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Thyroid Carcinoma
1. Initial Authorization
a. Cometriq will be approved based on the following criterion:
(1) One of the following:
(a) Diagnosis of medullary carcinoma
-OR-
© 2025 UnitedHealthcare Services, Inc.
1
(b) All of the following:
i. Diagnosis of one of the following:
• Follicular carcinoma
• Oncocytic cell carcinoma
• Papillary carcinoma
-AND-
ii. Disease is progressive after treatment with one of the following:
• Lenvima (lenvatinib)
• Nexavar (sorafenib)
-AND-
iii. Disease is at least one of the following:
• Symptomatic iodine-refractory
• Unresectable locoregional recurrent or persistent disease
• Distant metastatic disease
Authorization will be issued for 12 months.
2. Reauthorization
a. Cometriq will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Cometriq therapy
Authorization will be issued for 12 months.
C. Non-Small Cell Lung Cancer (NSCLC)
1. Initial Authorization
a. Cometriq will be approved based on both of the following criteria:
(1) Diagnosis of non-small cell lung cancer (NSCLC)
-AND-
(2) Positive for RET gene rearrangements
Authorization will be issued for 12 months.
2. Reauthorization
a. Cometriq will be approved based on the following criterion:
© 2025 UnitedHealthcare Services, Inc.
2
(1) Patient does not show evidence of progressive disease while on Cometriq therapy
Authorization will be issued for 12 months.
D. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim
logic. Use of automated approval and re-approval processes varies by program and/or
therapeutic class.
• Supply limits may be in place.
4. References:
1. Cometriq [prescribing information]. Alameda, CA: Exelixis, Inc.; August 2023.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/ . Accessed May 5, 2025.
Program Prior Authorization/Notification - Cometriq (cabozantinib)
Change Control
7/2013 Review of clinical criteria. No change to coverage. Updated formatting.
8/2014 Annual review. Added coverage for NSCLC, clarified thyroid cancer,
updated formatting, Background and References.
8/2015 Annual review with no change to clinical criteria. Increased authorization
and reauthorization from 11 months to 12 months for all indications.
Updated references.
6/2016 Annual review. Updated MTC clinical criteria to include only a diagnosis
of MTC. Updated background, formatting and references.
6/2017 Annual review. Changed MTC clinical criteria to Thyroid Cancer to
include NCCN expanded thyroid cancer indications. Updated background,
formatting and references.
6/2018 Annual review. Updated references.
6/2019 Annual review. Revised criteria for thyroid carcinoma. Updated
references.
© 2025 UnitedHealthcare Services, Inc.
3
6/2020 Annual review. Updated references.
6/2021 Annual review. No change to clinical criteria. Updated references.
6/2022 Annual review. Revised clinical criteria for thyroid carcinomas to align
with NCCN indications. Added NCCN Recommended Regimens to
coverage criteria. Updated references.
6/2023 Annual review. Updated Hürthle cell neoplasm to Oncocytic carcinoma in
background and criteria per NCCN guidelines. No change in clinical
intent of criteria. Updated references and added state mandate footnote.
6/2024 Annual review. Updated references.
6/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services, Inc.
4